Anticancer Drugs Naxitamab Oncology Pharmacology Physiotherapy

Naxitamab (Mechanism of Action)

In this article we will discuss Naxitamab (Mechanism of Action)

In this article, we will discuss Naxitamab (Mechanism of Action). So, let’s get started.

Mechanism of Action

Naxitamab-gqgk binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma
cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, naxitamab-gqgk was able to bind to cell surface GD2 and induce complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).


The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of naxitamab-gqgk have not been fully characterized.


The geometric mean (CV%) maximum plasma concentration (Cmax) of naxitamab-gqgk was 57.4 μg/mL (49%)
following Naxitamab 3 mg/kg intravenous infusion over 30 minutes.


The mean terminal half-life of naxitamab-gqgk was 8.2 days.


Naxitamab-gqgk is expected to be metabolized into small peptides by catabolic pathways.

Specific Populations

Population pharmacokinetic analyses suggest that age (range: 1 to 34 years), sex and race have no clinically important effect on the clearance (CL) of naxitamab-gqgk. The naxitamab-gqgk systemic exposure (AUC) at 150 mg/day (450 mg per cycle) for patients with body weight over 50 kg is not expected to differ clinically from that of the naxitamab-gqgk exposures at 3 mg/kg/day (9 mg/kg per cycle) for patients with body weight of 30 – 50 kg.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.